Bovine Colostrum Efficacy for the Treatment of Chronic Prostatitis Symptoms.
CompletedPhase 4NCT06804083
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a bothering condition characterized by pain localized to the pelvic, perineal and/or genital area and lower urinary tract symptoms (LUTS). Phytotherapy, which involves the combination of two or more active compounds, can be used to treat this challenging condition. The aim of this study was to investigate the role of an oral combination of colostrum and Serenoa repens extracts (PROSTYM®) in the treatment of CP/CPPS patients. The main questions the present study aims to answer are: * Does PROSTYM® enhance quality of life of CPP/CPPS patients? * Does it help reducing pain symptoms of CPP/CPPS patients? Researchers will investigate whether PROSTYM® works to treat CPP/CPPS symptoms, so its efficacy, but also its tolerability and adherence to therapy. Participants will: * Take PROSTYM® every day for 6 months; * Visit the clinic for follow-up visits at 3 and 6 months; * Answer validated questionnaires and declare potential adverse events at follow-up visits.
Study details
- Official title
- Oral Immunoglobulins From Bovine Colostrum and Anti-inflammatory Extracts in Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Prospective Study
- Conditions
- Chronic Prostatitis (CP)
- Chronic Prostatitis With Chronic Pelvic Pain Syndrome
- Chronic Prostatitis/ Pelvic Pain Syndrome
- Interventions
- Drug: oral combination of colostrum and Serenoa repens extracts (PROSTYM®)
- Sponsor
- Clinica Urologica Molinette - Città della Saliute e della Scienza
- Collaborators
- A.O.U. Città della Salute e della Scienza - Molinette Hospital
- Start date
- 2020-03-01
- Primary completion
- 2022-12-31
- Sex
- Male
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Italy
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * adult male patients (aged \>18 years) * clinical affection by CP/CPPS with symptoms that persisted for ≥6 months; * CPSI pain domain score ≥5 points; * negative Meares and Stamey test score. Exclusion Criteria: * patients with prevalent BPH symptoms (CPSI pain domain \<5), acute prostatitis, chronic bacterial prostatitis (positive Meares and Stamey test), prostate or bladder cancer, urethral stenosis or neurological bladder; * no other drug or supplement specific to chronic prostatitis in the previous 30 days.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06804083